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Background: Abnormal misfolded tau protein is a driving force of neurofibrillary degeneration in Alzheimer’s
disease. It has been shown that tau oligomers play a crucial role in the formation of intracellular neurofibrillary
tangles. They are intermediates between soluble tau monomers and insoluble tau filaments and are suspected
contributors to disease pathogenesis. Oligomeric tau can be released into the extracellular space and spread
throughout the brain. This finding opens the question of whether brain macrophages or blood monocytes have
the potential to phagocytose extracellular oligomeric tau.
Methods: We have used stable rat primary microglial cells, rat peripheral monocytes-derived macrophages, BV2
microglial and TIB67 macrophage immortalized cell lines that were challenged by tau oligomers prepared by an
in vitro aggregation reaction. The efficiency of cells to phagocytose oligomeric protein was evaluated with confocal
microscopy. The ability to degrade tau protein was analyzed by immunoblotting.
Results: Confocal microscopy analyses showed that macrophages were significantly more efficient in phagocytosing
oligomerized tau proteins than microglial cells. In contrast to macrophages, microglia are able to degrade the
internalized oligomeric tau only after stimulation with lipopolysaccharide (LPS).
Conclusions: Our data suggests that microglia may not be the principal phagocytic cells able to target extracellular
oligomeric tau. We found that peripheral macrophages display a high potency for elimination of oligomeric tau and
therefore could play an important role in the modulation of neurofibrillary pathology in Alzheimer’s disease.
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Neuroinflammation plays a key role in the modulation of
the pathogenesis of neurodegenerative disorders such as
Alzheimer’s disease (AD) and related tauopathies [1-3]. In
AD, activated microglia may become neurotoxic through
their increased expression of pro-inflammatory cytokines,
which lead to extensive neuronal death and disease mani-
festation [4,5]. Prolonged activation of microglia might
impair their lysosomal enzymatic complex and such ‘frus-
trated phagocytes’ are not able to remove AD pathological
lesions [6,7]. Another study demonstrated that microglia* Correspondence: Norbert.Zilka@savba.sk
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unless otherwise stated.could internalize Aβ plaques but they released it back into
the medium without degradation [8].
It has been hypothesized that macrophages which in-
filtrate the brain could be more effective in the recogni-
tion and subsequent elimination of the pathological
lesions than resident microglia [9]. Simard et al. [10]
showed that circulating cells such as monocytes could
be responsible for effective phagocytosis and degradation
of amyloid plaques in transgenic AD mice. Furthermore,
peripheral macrophages were found to be particularly ef-
ficient in phagocytosing synthetic Aβ peptides [11].
Distribution of activated microglia parallels that of tau
deposits in human AD [12-16] and non-AD tauopathies
such as tangle-predominant dementia, progressive supra-
nuclear palsy, corticobasal degeneration and Pick’s disease
[17-21]. Activated microglia have been frequently present
in the proximity of neurofibrillary tangles at early and lateal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ship between inflammatory response and tau neurofibril-
lary lesions [14]. The activation of microglia linked to tau
deposition has been also observed in various tau trans-
genic models [22-27].
Several previous studies have demonstrated that extra-
cellular tau proteins play an important role in AD neuro-
inflammation [28-30]. It was shown that the oligomeric
tau that represents an early stage of tangle formation can
be released into the extracellular space, where it behaves
as a transmissible agent, spreading tau pathology through-
out the brain in a ‘prion-like fashion’ [31-33].
These findings raise the question of whether brain
macrophages or peripheral monocytes entering the brain
have the potential to phagocytose extracellular oligo-
meric tau and thus eliminate its toxic function. There-
fore we have investigated the ability of BV2 microglia,
immortalized TIB67 macrophages cell lines, peripheral
blood monocytes-derived macrophages and primary
microglia to phagocytose and degrade tau oligomers.
Misfolded truncated tau was used as a template for tau
oligomerization. Truncated tau species was identified by
two monoclonal antibodies (MN423 and DC11) in the
human AD brain [34-36]. The truncated tau used in this
study was previously shown to induce abnormal micro-
tubular assembly in vitro [37] and extensive neurofibril-
lary degeneration in vivo [37,38].
In this study we found that peripheral blood monocyte-
derived macrophages (PB-MoM) and immortalized TIB67
macrophages are more proficient in the phagocytosis and
degradation of oligomerized truncated tau than primary
microglial cells or immortalized BV2 microglia.
Materials and methods
Expression and purification of recombinant tau protein
Human truncated tau151-391 (numbering according to
the longest human tau isoform Tau40) was expressed
in Escherichia coli strain BL21(DE3) (Sigma-Aldrich, St.
Louise, Missouri, United States) from a pET-17 expression
vector and purified from bacterial lysates as described pre-
viously [39], except that the phosphocellulose step was
omitted and size-exclusion chromatography was per-
formed in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4, pH 7.4) (AppliChem GmbH,
Darmstadt, Germany). Purified tau protein was stored in
PBS in working aliquots at −70°C. The purity of tau protein
was subsequently verified by gradient SDS gel electrophor-
esis (5 to 20% gel), Coomassie blue staining and Western
blot analysis with DC25 antibody (AXON Neuroscience SE
(Bratislava, Slovakia), recognizes residues 347–354 of the
longest human tau isoform Tau40). The fluorescently
tagged tau protein was prepared by labelling with Alexa
Fluor 546 (Invitrogen, Carlsbad, California, United States)
according to the manufacturer’s recommendations.Tau filament assembly and detection of tau oligomers
In vitro oligomerization of recombinant truncated tau
protein (aa 151–391, 100 μM) was carried out using
heparin (Sigma-Aldrich, St. Louis, Missouri, United
States) as an inducer at a final concentration of 25 μM
in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4, pH 7.4) The reaction was performed
overnight (for at least 12 hours) at 37°C. After incuba-
tion, tau oligomers were collected by centrifugation at
100,000 × g for 1 hour at room temperature and the
pellet was re-suspended in PBS and sonicated for 5 sec-
onds at 20% power output using an MS72 probe of a
Bandelin Sonopuls Sonifier (Bandelin, Berlin, Germany).
Subsequently, 1 μM aliquots were stored at -70°C. The
oligomerization of the tau protein was verified by SDS
gel electrophoresis, quantitative thioflavin T (ThT) fluor-
escence spectroscopy with excitation at 450 nm and
emission at 510 nm, and by electron microscopy.
Transmission electron microscopy
For morphological examination of in vitro oligomerized
tau by electron microscopy the oligomers collected by
centrifugation were dissolved in pure water (Merck
Millipore, Darmstadt, Germany) and placed on carbon-
coated 400 mesh copper grids (Christine Gröpl, Austria)
for 2 minutes. Grids were washed with pure water for 2
minutes and the tau oligomers were negatively stained
with 2% uranyl acetate for 1 minute (Sigma-Aldrich, St.
Louis, Missouri, United States). The stained grids were
immediately analyzed using an FEI Morgagni 268 elec-
tron microscope (Czech Republic).
Cell cultivation
Mouse microglial BV2 cells (C57BL/6, purchased from
ICLC, Modena, Italy) and mouse macrophages J774A.1
(TIB67™, purchased from ATCC™ (American Type Culture
Collection (ATCC), La Jolla, California, United States)
were cultivated in Dulbecco’s Modified Eagle’s Medium
(DMEM, PAA laboratories GmbH, Colbe, Germany) con-
taining 10% Fetal calf serum (FCS) (Invitrogen, Carlsbad,
California, United States), and 2 mM L-glutamine (PAA
laboratories GmbH, Colbe, Germany) at 37°C and 5%
CO2. The medium was changed twice a week.
Primary microglial culture
Cerebral cortices of newborn Sprague Dawley rats (Institute
of Neuroimmunology, Bratislava, Slovakia) (1 day old)
were dissected by cervical dislocation, stripped of their
meninges, and mechanically dissociated by repeated
pipetting followed by passing through a nylon mesh.
Cells were plated in 96-well plates and 75 cm2 flasks
pre-coated with poly-L-lysine (10 mg/ml) and cultivated
in DMEM containing 10% FCS and 2 mM L-glutamine (all
from Life Technologies Invitrogen, Carlsbad, California,
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atmosphere. The medium was changed twice a week.
Mixed glial cultures reached confluence after 8 to 10
days in vitro. Confluent mixed glial cultures were sub-
jected to mild trypsinization (0.05 to 0.12%) in the pres-
ence of 0.2 to 0.5 mM Ethylenediaminetetraacetic acid
(EDTA). This resulted in the detachment of an intact
layer of cells containing astrocytes, leaving undisturbed
a population of firmly attached cells identified as more
than 98% microglia [40]. The cells were maintained in
astrocyte-conditioned medium and were used for exper-
iments after 24 hours in culture. The purity of micro-
glial cell cultures isolated by this procedure was 95%
(CD11b/CD18 staining).
Peripheral blood monocyte-derived macrophages (PB-MoM)
Rat blood monocytes were obtained from the peripheral
blood of healthy Sprague Dawley rat males (5-months-
old). Aseptically, 8 ml of Ficoll-Paque Plus (GE Health-
care, Uppsala, Sweden) were added into a clean centrifuge
tube. A total of 4 ml of blood samples diluted with sterile
PBS 1:1 were carefully layered on Ficoll-Paque Plus (GE
Healthcare, Uppsala, Sweden) and centrifuged at 300 × g
for 30 minutes at 25°C.
Using a sterile Pasteur pipette the lymphocyte layer
was transferred into a clean centrifuge tube and resus-
pended in PBS. The cells were centrifuged at 300 × g
for 15 minutes at 25°C. Isolated cells were cultivated in
Roswell Park Memorial Institute (RPMI) 1640 medium
containing 20% FCS and 2 mM L-glutamine for 2 days.
Then the cells were differentiated into peripheral blood
monocyte-derived macrophages (PB-MoM) with gran-
ulocyte colony-stimulating factor GM-CSF (100 ng/ml)
for a further 6 days.
Cell stimulation
One day prior to the challenge of the cells with latex beads
or tau oligomers, cell culture medium was replaced
with serum-free DMEM medium with L-glutamine. To
stimulate the cells, lipopolysaccharide (LPS) from E. coli
(Sigma-Aldrich, St. Louis, Missouri, United States) was
added to the medium for a final concentration of 250 ng/
ml for 24 hours. This concentration of LPS had minimal
effect on cell viability (data not shown).
Phagocytosis assay
TIB67 macrophages and BV2 microglia cells were plated
on 6-well plates at a density of 5 × 103 cells/cm2. They
were cultivated in the presence (stimulated) or absence
(non-stimulated) of LPS and subsequently challenged ei-
ther with 1 μM oligomeric tau (labelled with Alexa Fluor
546) or with red fluorescent latex beads (2 μm, L3030,
Sigma-Aldrich, St. Louis, Missouri, United States) for
2, 6 and 24 hours in DMEM medium supplementedwith L-glutamine without serum. The experiments were
performed in triplicate. The phagocytic activities of the
cells were evaluated by in vivo cell imaging, flow cytom-
etry and Western blot analysis.
In vivo cell imaging
Cells were plated (at a density of 5 × 103 cells/well) on
Lab-tek chamber slides (Thermo Scientific, Rockford,
Illinois, United States) pre-coated with poly-L-lysine
(Sigma-Aldrich, St. Louis, Missouri, United States) and
cultivated for 24 hours in DMEM medium with serum.
For visualization of live cells we used MitoTracker™ Green
FM green-fluorescent mitochondrial stain (final concen-
tration of 200 nM, Invitrogen, Carlsbad, California, United
States). Staining was done for 30 minutes under normal
growth conditions. After staining the solution was re-
placed with fresh pre-warmed Hank’s solution (Sigma-
Aldrich, St. Louise, Missouri, United States and cells were
examined by LSM 710 confocal microscope (Zeiss, Jena,
Germany). At least 100 cells per chamber were analyzed
for quantification, totalling ten chambers per experiment.
Western blot analysis
Cells were plated at a density of 5 × 103 cells/cm2 in a 6-
well plates and cultivated with 1 μM oligomeric tau pro-
tein for 2, 6 and 24 hours. Before cell lysis, the cells were
incubated with 0.05% trypsin for 3 minutes at 37°C to
remove tau bound to the cell surface, the residual tryp-
sin activity was blocked with 1% bovine serum albumin
(BSA) in PBS for 30 minutes at room temperature and
then the cells were harvested into lysis buffer (200 mM
Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4,
20 mM NaF, 0.5% Triton X-100, 1 × protease inhibitors
complete EDTA-free from Roche, Mannheim, Germany).
Total protein concentration of prepared cell extracts
was measured by Bio-Rad protein assay (Bio-Rad
laboratories GmbH, Colbe, Germany). A total of 25 μg
of the proteins was separated onto 12% SDS-polyacrylamide
gels and transferred to nitrocellulose membrane in 10
mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS,
pH 11, Roth, Karlsruhe, Germany). The membranes
were blocked in 5% milk in Tris-buffered saline/Tween
20 (Sigma-Aldrich, St. Louis, Missouri, United States)
(TBS-T, 137 mM NaCl, 20 mM Tris-base, pH 7.4, 0.1%
Tween 20) for 1 hour and incubated with primary anti-
body (DC25 antibody) overnight at 4°C. Membranes
were incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody in TBS-T (1:3000, Dako,
Glostrup, Denmark) for 1 hour at room temperature.
Immunoreactive tau proteins were detected by chemilu-
minescence (SuperSignal West Pico Chemiluminescent
Substrate, Thermo Scientific, Pittsburgh, United States) and
the signals were digitized by Image Reader LAS-3000
(FUJIFILM, Bratislava, Slovakia).
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Each experiment was repeated at least three times. Data
are presented as mean ± standard error of the mean
(SEM). Friedman’s repeated measures one-way analysis
of variance (ANOVA) on ranks and Dunn’s method for
multiple comparisons were used. Student’s t-test was
used for assessment of the difference between groups.
Statistical significance was defined as P <0.05.
Results
Characteristic features of tau oligomers
A characteristic feature of most neurodegenerative disorders
is the accumulation of protein aggregates and pathologically
modified protein forms. In order to analyze the phagocytic
activities of microglia and macrophages we used insoluble
tau oligomers generated in vitro. The oligomers were pre-
pared from recombinant truncated tau (aa 151–391 of
the longest human tau isoform Tau40) tagged with fluores-
cent dye Alexa Fluor 546 (Invitrogen, Carlsbad, California,
United States). In vitro oligomerization of the recombinant
truncated tau protein was induced by polyanionic ag-
gregation inducer heparin. The reaction was allowed to
proceed overnight at 37°C. To evaluate the progress of tau
oligomerization we used thioflavin T fluorescence. Tau
oligomerization increased in time with the highest fluores-
cent signal after 12 hours of incubation (Figure 1A).
We analyzed tau oligomers by Western blot analysis
(detection with DC25 antibody, amino acids 347–354) and
electron microscopy. Western blot showed higher molecu-
lar weights tau oligomers (45–170 kDa, Figure 1B).
Morphological examination of the oligomeric tau by
transmission electron microscopy revealed the presence
of small circular oligomers with diameters ranging from
10 to 30 nm and short filaments up to 120 nm long with
a width of 10 to 15 nm (Figure 1C), similar to those de-
scribed by Friedhoff et al. [41].Figure 1 Characterization of tau oligomers. Oligomerized tau protein (t
polyanionic inducer heparin. Progress of tau oligomerization was monitore
oligomerization reaction produced significant thioflavin T fluorescence ove
molecular weight on SDS-PAGE is 30 kDa) and oligomerized tau (45 to 170
antibody DC25 (epitope 347–354 of human tau isoform Tau40) (B), which
microscopy (C) showed tau oligomers in the form of small round particlesImmortalized TIB67 macrophages are more effective in
phagocytosis of tau oligomers than BV2 microglia cell line
To evaluate the mechanism of elimination of extracellular
oligomeric tau present in the brains of tauopathy patients,
we analyzed phagocytic activity of BV2 mouse microglia
cell line, a widely used valid model of microglial cells
[42,43], and monocytic/macrophage cell line J774A.1
(ATCC™ TIB67™) as a surrogate for primary macrophages
[44]. Each experiment consisted of three replicates of
cultures to confirm our findings. Three independent
batches of cultures (BV2 and TIB67) or two or three in-
dependent isolations of either primary microglia or
monocytes-derived macrophages were used (Additional
file 1: Table S1).
The phagocytic study investigated four parameters: 1)
phagocytic capacity (non-activated and activated) of the
phagocytes against particulate matter, evaluated by stan-
dardized homogeneous particles, 2) phagocytic capacity
(non-activated and activated) against abnormal oligo-
merized tau proteins, 3) temporal characterization of the
phagocytic potency and 4) potency to degrade the inter-
nalized abnormal tau proteins. The first three parame-
ters were analyzed using in vivo cell imaging and flow
cytometry. The tau degradation activities were evaluated
by Western blotting.
Phagocytic activity largely depends on the particle size.
Several studies reported that maximal phagocytosis was
observed for particle size with a diameter of about 2 μm
and that phagocytosis decreased with increasing particle
size [45]. Therefore, we characterized the phagocytic
capacity of microglia and macrophages with standard
red fluorescent latex beads with a diameter of 2 μm in
activated (by LPS) and non-activated states. The process
of phagocytosis was monitored by live fluorescent mi-
croscopy over the period of 24 hours at three independ-
ent time points (2, 6 and 24 hours). Individual cells wereau151-391) was prepared by in vitro oligomerization reaction using
d by thioflavin T fluorescence (A). Neither tau nor heparin alone in the
r the time course of the experiment. Monomeric tau (25 kDa, apparent
kDA) was analyzed by Western blot and visualized by monoclonal
revealed multiple SDS-stable oligomeric species. Transmission electron
and short filaments (arrows). Scale bar represents 200 nm.
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Green FM.
The activity of TIB67 in internalizing latex beads did
not significantly differ over time, although it showed
tendency towards increasing activity (Figure 2A, non-
activated cells/–LPS: P = 0.112; activated cells/+LPS:
P = 0.103). We quantified the percentage of latex beads-
positive TIB67 macrophages after 2 hours (−LPS: 40% ±
2.1% versus + LPS: 56% ± 1.9%; P = 0.012), after 6 hours
(−LPS: 54% ± 1.4% versus + LPS: 66% ± 0.7%; P = 0.25)
and after 24 hours (−LPS: 69% ± 3% versus + LPS: 88% ±
1.6%; P = 0.01). Importantly, LPS treatment increased cell
phagocytic activity with statistical significance at 2 and 24
hours (Figure 2A).
Compared to TIB67 macrophages, BV2 microglia cells
showed decreased potency in phagocytosis of the latex
beads. No beads-positive BV2 microglia cells (stimulated
with LPS or not) were observed after 2 and 6 hours.
The ability of BV2 microglia to engulf latex beads
significantly increased during 24 hours both underFigure 2 Comparative immunofluorescent analysis uncovered the hig
comparing to BV2 microglia. Live phagocytes were labelled with MitoTra
challenged with red fluorescent latex beads or with oligomeric tau labelled w
macrophages (A), BV2 microglia (B) engulfing red fluorescent beads in the pr
and BV2 phagocytosis of latex beads after 24 hours. Quantification of TIB67 m
the presence or absence of LPS treatment. (F) Quantitative comparison of TIB
hours. The experiments were run in triplicates. Data are presented as mean ±
P <0.05 (*) or P <0.01 (**). Abbreviation: P, p-value.normal conditions and after stimulation with LPS (−LPS:
P = 0.0046; +LPS: P = 0.0001), but even then it remained
negligible in comparison to macrophages. As was the
case for macrophages, statistical analysis revealed that
LPS treatment significantly increased their phagocytic
activity only after 24 hours (Figure 2B, +LPS: 2.6% ±
0.3% versus –LPS: 1.3% ± 0.5%; P = 0.0015).
Thus, the overall quantification showed that the ability
of macrophages to phagocytose particulate matter (ex-
emplified by the latex beads) was higher compared to
BV2 cells (Figure 2C). We found that after 24 hours 69%
(±0.03%) of macrophages contained engulfed latex beads,
compared to only 1.3% (±0.5%) of BV2 microglia
(Figure 2C, P = 0.003). After LPS stimulation we de-
tected 88% (±1.6%) beads-positive TIB67 macrophages
but only 2.6% (±0.3%) beads-positive BV2 microglia
(Figure 2C, P = 0.008).
In order to characterize the tauopathy-relevant phago-
cytic activity of the two types of phagocytes, we chal-
lenged the cultivated cells with oligomerized tau. Theher potency of TIB67 macrophages phagocytose tau oligomers
cker™ Green FM green-fluorescent mitochondrial stain and then
ith red Alexa Fluor 546. The panels show quantification data of TIB67
esence or absence of LPS treatment. (C) Quantitative comparison of TIB67
acrophages (D) and BV2 microglia (E) phagocytosing tau oligomers in
67 and BV2 primary microglia cell phagocytosis of tau oligomers after 24
standard error of the mean (SEM). Statistical significance was defined as
Figure 3 Confocal imaging showing that TIB67 macrophages
are more efficient in phagocytosis of tau oligomers than BV2
microglia. Confocal cross-section analyses of cells show a higher
number of tau oligomers engulfed by macrophages than by BV2
microglial cells. Micrographs show tau oligomers positive TIB67
macrophages non-treated (A) or treated with LPS (B). Cross-sections
show that tau is internalized within the cells. Tau oligomer positive
BV2 cells without and with LPS stimulation are shown in panels
(C) and (D), respectively. LPS-stimulated microglia contain tau
oligomers internalized, while non-stimulated cells have tau particles
rather attached to the outside of the cells. Scale bar: 20 μm.
Abbreviation: μm, micrometer.
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mers appeared very similar to their activity towards latex
beads. The quantification of the percentage of oligomer-
ized tau-positive macrophages showed that after 2 hours
more than one third of all cells contained internal-
ized tau oligomers (Figure 2D, 39% ± 2.3%), which in-
creased over time to almost two thirds after 24 hours
(Figure 2D, 6 hours: 51% ± 1.1%; 24 hours: 62% ± 3.1%).
LPS-stimulated macrophages exhibited increased (albeit
not significantly) phagocytic activity at all time points
(Figure 2D, 2 hours: 54% ± 1.9%, –LPS versus + LPS
P = 0.47; 6 hours: 60.3% ± 1.9%, −LPS versus + LPS
P= 0.18; 24 hours: 79% ± 2.7%, −LPS versus + LPS P = 0.18).
The ability of TIB67 macrophages to phagocytose tau
oligomers significantly increased over time only after
LPS treatment (Figure 2D, +LPS: P = 0.044; −LPS:
P = 0.2). It is important to note that LPS stimulation
had a rather minor effect on the phagocytosis of tau
oligomers by macrophages.
Analysis of phagocytic activity of BV2 microglia revealed
that less than 15% of all cells were able to internalize tau
oligomers at any time point (Figure 2E, −LPS). LPS stimu-
lation did not increase this phagocytic activity during the
first 6 hours (2 hours: −LPS 10.3% ± 0.8%, +LPS 8.7% ±
0.09%, P = 0.45; 6 hours: −LPS 10.2% ± 0.5%, +LPS
11.4% ± 0.3%, P = 0.36) and only slightly after 24 hours
(−LPS: 11.6% ± 0.6%; +LPS: 17.4% ± 0.3%, P = 0.011).
This LPS-stimulated phagocytic activity significantly in-
creased with time (P = 0.021).
Our comparative study revealed that the number of oli-
gomerized tau-positive TIB67 macrophages was more
than five times higher than the number of tau positive
BV2 microglia cells (Figure 2F, 62% ± 3.1% versus 11.2% ±
0.6%; P = 0.003). Similar results were obtained after LPS
stimulation (Figure 2F, 78.7% ± 2.7% versus 15.4% ± 0.3%,
P = 0.004).
We used the z-stacking function of the laser scanning
confocal microscope to confirm that the tau oligomers
are indeed internalized and not just attached to the out-
side of the cells (Figure 3). Confocal images of the
phagocytes after 24 hours of incubation with tau oligo-
mers showed that oligomerized tau (red) is localized
within the cell bodies (green) of TIB67 macrophages
(Figure 3A - without LPS stimulation, Figure 3B - with
LPS stimulation). In the case of non-stimulated BV2
microglia, there is a smaller amount of tau oligomers as-
sociated with the cells and it seems rather attached to
the outside of the cells (Figure 3C). On the other hand,
LPS-stimulated microglia contain larger amounts of tau
within the cells, although the amount is still smaller than
that found in macrophages (Figure 3D). These observa-
tions support data coming from our quantitative study
where we found that BV2 microglia are less potent in
phagocytosing tau oligomers than TIB67 macrophages.Peripheral rat blood monocyte-derived macrophages are
more effective in phagocytosis of tau oligomers than rat
primary microglia
In order to show that our analysis is relevant to an in vivo
situation, we tested the phagocytic activity of primary
microglial cells and peripheral rat blood monocyte-derived
macrophages (PB-MoM) as well.
The activity of PB-MoM in internalizing latex beads
increased over time (Figure 4A, non-activated cells/–
LPS: P = 0.0015; activated cells/+LPS: P = 0.0019). We
quantified the percentage of latex beads-positive PB-
MoM after 2 hours (−LPS: 15% ± 1.2% versus + LPS:
25% ± 1%; P = 0.052), after 6 hours (−LPS: 51% ± 1.4%
versus + LPS: 68% ± 1%; P = 0.23) and after 24 hours
(−LPS: 100% ± 0.3% versus + LPS: 100% ± 0.6%). Import-
antly, LPS treatment did not increase the cell phagocytic
activity over time.
The potency of primary microglia to engulf latex
beads increased during 24 hours both under normal
conditions and after stimulation with LPS (Figure 4B, −LPS:
P = 0.0002; +LPS: P = 0.001). After 24 hours, the phagocytic
Figure 4 Immunofluorescent study reveals a higher efficacy of peripheral blood-derived monocytes to phagocytose tau oligomers than
primary microglia. The panels show quantification data of PB-MoM macrophages (A) and primary microglia (B) engulfing oligomerized beads
in the presence or absence of LPS treatment. (C) Quantitative comparison of PB-MoM macrophages and primary microglia phagocytic efficacy
of beads oligomers after 24 hours. Quantification of PB-MoM macrophages (D) and primary microglia (E) phagocytosing tau oligomers in the
presence or absence of LPS treatment. (F) Quantitative comparison of PB-MoM macrophages and primary microglia and primary microglia cells
phagocytosis of tau oligomers after 24 hours. The experiments were run in triplicates. Data are presented as mean ± standard error of the mean
(SEM). Statistical significance was defined as P <0.05 (*) or P <0.01 (**). Abbreviations: SEM, standard error of the mean; P, p-value; PB-MoM,
Peripheral blood monocyte-derived macrophages.
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peripheral macrophages (Figure 4B, −LPS: 10.8% ± 0.6%
versus + LPS: 19.3% ± 1%). Strikingly, LPS treatment signifi-
cantly increased the cell phagocytic activity after 24 hours
(P = 0.0035).
We found that after 24 hours, 100% of peripheral rat
blood monocyte-derived macrophages contained engulfed
latex beads, while only 10.8% (±0.5%) of primary microglia
showed such inclusions (Figure 4C, P = 0.001). After LPS
stimulation we detected 100% beads-positive macro-
phages, but only 19.3% beads-positive primary microglia
(Figure 4C, P = 0.0012).
The analysis of the phagocytosis of tau oligomers by
peripheral rat blood monocyte-derived macrophages
and primary microglia revealed interesting differences.PB-MoM exhibited an extremely high ability to phagocyt-
ose oligomerized tau. The quantification of the percentage
of oligomerized tau-positive PB-MoM increased over time
(Figure 4D, 2 hours: 19% ± 1.3%; 6 hours: 69% ± 2.1%; 24
hours: 100% ± 0.1%; P = 0.011). LPS-stimulated macro-
phages exhibited increased (but not significantly) phago-
cytic activity at all time points (Figure 4D, 2 hours: 24% ±
0.9%; 6 hours: 77.3% ± 1.8%; 24 hours: 100% ± 0.7%). Simi-
larly to TIB67 cells, LPS stimulation had no effect on
phagocytosis of tau oligomers by peripheral rat blood
monocyte-derived macrophages.
Primary microglial cells displayed limited phagocytic ac-
tivity during the 6-hour incubation time, even after LPS
stimulation (Figure 2E, 2 hours: −LPS 0.3% ± 0.08%, +LPS
0.42% ± 0.009%, P = 0.65; 6 hours: −LPS 1.8% ± 0.05%, +LPS
Figure 5 Confocal study showed that peripheral blood-derived
monocytes are more efficient in phagocytosis of tau oligomers
than primary microglia. Confocal cross-section analyses of cells
showed higher number of tau oligomers engulfed by macrophages
as by BV2 microglial cells. Micrographs show tau oligomers positive
TIB67 macrophages non-treated (A) or treated with LPS (B). The pictures
demonstrate that almost all macrophages engulfed oligomeric tau.
Primary microglia phagocytosing tau oligomers in the presence or
absence of LPS treatment are shown in panels (C) and (D). Primary cells
showed higher ability to phagocyte tau oligomers after LPS stimulation.
Scale bar: 20 μm. Abbreviations: μm, micrometer;
LPS, lipopolysaccharide.
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stimulation only after 24 hours (−LPS: 26.4% ± 0.3%, +LPS:
42.6% ± 0.6%, P = 0.01).
Thus, the overall quantification showed that the ability
of peripheral rat blood monocyte-derived macrophages
to phagocytose oligomerized tau was higher compared
to primary microglia (Figure 4F). We found that after
24 hours 100% of PB-MoM macrophages contained
engulfed oligomerized tau, compared to only 26.4% of
primary microglia (Figure 2F, P = 0.001). After LPS
stimulation we detected 100% tau positive PB-MoM
macrophages and 42.6% tau-positive primary microglia
cells (Figure 4F, P = 0.0014).
Our comparative study revealed that the number of
oligomerized tau-positive PB-MoM macrophages was al-
most four times higher than the number of tau positive
primary microglia cells in the absence of LPS, and two
times higher after stimulation with LPS.
A confocal study revealed that PB-MoM are very effect-
ive in phagocytosis of tau oligomers regardless of LPS
treatment (Figure 5A,B). In the case of non-stimulated
primary microglia cells, there is a smaller amount of tau
oligomers associated with the cells (Figure 5C), while
LPS-stimulated microglia seems to be more effective in
phagocytosis of tau oligomers than non-treated micro-
glia (Figure 5D).
Western blot analysis revealed that LPS stimulation increased
degradation of tau oligomers by macrophages and microglia
In order to evaluate the ability of macrophages to de-
grade phagocytosed tau oligomers we analyzed the pres-
ence of internalized tau by Western blot analysis. For
total tau staining we used phosphorylation independent
antibody DC25. The Western blot showed a decrease of
oligomeric tau with time in the cell lysates from macro-
phages and microglia (Figure 6A,B,C,D, lane ‘2 hours’
compared to ‘6 hours’ and ‘24 hours’). Interestingly,
TIB67 macrophage cells can phagocytose oligomeric tau
regardless of LPS treatment, however the efficacy is
higher after LPS stimulation (Figure 6A). Neither BV2
microglia nor primary microglia are able to degrade tau
oligomers without LPS treatment (Figure 6B,D).
Discussion
Alzheimer’s disease (AD) is a widespread progressive
neurodegenerative disorder characterized by the pres-
ence of neurofibrillary tangles consisting of hyperpho-
sphorylated and truncated tau proteins and extracellular
senile plaques composed of amyloid-β [46-51]. Previous
studies have indicated that neuroinflammation signifi-
cantly modulates the pathogenesis of AD by increased
activation of brain immune cells and their potency to
phagocytose and enzymatically degrade pathologic le-
sions [52-54].In early stages of AD, microglia activation becomes pro-
tective and delays the disease progression by effective clear-
ance of pathological lesions [55-57], while in the later
stages, microglia lose their protective function and release
pro-inflammatory cytokines such as tumor necrosis factor-
alpha (TNF-α) and interleukin-1beta (IL-1β) [4,5,58-60]. It
was shown that microglia cells isolated from the aged
brains exhibit increased release of cytokines as compared to
those from the young brains, suggesting an elevated inflam-
matory state in aged microglia [61].
The issue of whether microglia are able to eliminate
pathological lesions such as neurofibrillary tangles or
senile plaques from AD brain still remains the matter
of controversy. Wisniewski et al. [6] observed that hu-
man brain-resident microglia cells appeared in the close
proximity of amyloid plaques but they did not contain
β-amyloid fibrils in their lysosomal compartment. In
Figure 6 Macrophages and microglia can degrade tau oligomers. Western blot analyses of extracts from TIB67 macrophages (A), BV2
microglia (B), peripheral blood monocyte-derived macrophages (C) and primary microglia (D) challenged with oligomerized (misfolded) tau for 2,
6 and 24 hours showed that macrophages are more potent in degradation of tau oligomers than microglia. Microglia were able to phagocytose
and degrade tau oligomers only after LPS stimulation. Western blots were developed with DC25 antibody. w/o, without. Abbreviations: w/o,
without; LPS, lipopolysaccharide.
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human microglia cells obtained from AD brains could
engulf Aβ [52,62], however they could not degrade fibrillar
Aβ [8,63]. Microglia with a defective lysosomal enzymatic
complex have weak acidic lysosomes, which would de-
crease the activity of many proteases and could lead to the
inability to degrade Aβ effectively [64]. On the other hand,
it has been suggested that the acidic conditions in micro-
glial endosomes and lysosomes can promote assembly or
growth of fibrillar Aβ plaques, which could then be re-
leased from the cells into the extracellular space [65-67].It was shown that tau oligomers were significantly elevated
in the AD brain, preceded the tangle formation and had
contributed to the progression of tau neurodegeneration
[31,32]. In our study, we used recombinant truncated tau
(aa 151-391/4R) derived from AD brains [37] to prepare
tau oligomers. In order to analyze phagocytic activity of
microglia we used immortalized mouse microglia cell line
BV2 and primary microglial cells. Several research papers
have demonstrated that BV2 cells can be used as alterna-
tive model system for primary microglia cultures for ex-
periments examining brain inflammation, and faithfully
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as exhibit a robust phagocytic response [69-71]. Our re-
sults show that neither primary microglial cells nor BV2
microglia were able to effectively phagocytose oligomeric
tau when compared with macrophages. However, after ac-
tivation with LPS, the phagocytic activity of both primary
microglial cells and BV2 cells increased. Previously, Cooper
et al. [72] found that LPS could increase the phagocytic
activity of microglia via increased Fc receptor capacity.
Further, phagocytosis-related events, such as enhanced
hexose monophosphate shunt activity, H2O2 formation
and nitroblue tetrazolium reduction could also be stimu-
lated by LPS [72]. We can hypothesize that LPS stimulation
can activate molecular pathways involved in phagocytosis
of tau oligomers.
Our Western blot analyses showed that LPS can stimu-
late degradation of oligomeric tau. Treatment with inflam-
matory agents such as LPS probably acidifies microglial
lysosomes and thus increases degradation of oligomerized
tau protein. It has been shown that stimulation by LPS in-
creased the expression of CD68 that is responsible for
lysosomal activity [73]. This indicates that acute inflamma-
tion can improve the microglial ability to phagocytose
oligomeric tau.
The question of whether blood-borne leukocytes can
penetrate into the AD brain yielded contradictory results.
Some authors proposed that the chronic inflammatory re-
sponse implicated in AD was provided almost exclusively
by resident CNS cells without any apparent influx of leuko-
cytes from the blood [3,74]. Others have demonstrated that
hematopoietic cells can enter the AD brain [75-78] or ro-
dent model brain [26,79,80]. Some animal studies using
bone marrow transplant with green fluorescent protein-
expressing myeloid cells suggest that monocytes are re-
cruited to the brain parenchyma, where they evolve mor-
phologically and functionally into microglia [81]. It was also
shown that no brain resident microglia cells but circulating
peripheral monocytes could be responsible for the phago-
cytosis and degradation of senile plaques in rat and human
brain [81]. Fiala et al. [82] also showed that peripheral mac-
rophages are highly capable of phagocytosing synthetic Aβ
peptides. On the other hand, the presence of β-amyloid fi-
brils was observed in lysosomes of peripheral macrophages
that infiltrated the brains of AD patients after stroke.
Here we show that macrophages are more effective in
the phagocytosis of tau oligomers, the main component
of neurofibrillary tangles in AD, than microglial cells.
Our finding that macrophages succeed in the degrad-
ation of tau oligomers has provided insight into the pos-
sibility of utilizing them for targeted cell therapy for AD.
Conclusions
Our data suggests that similar to the case with Aβ, micro-
glia are not efficient enough to remove extracellularoligomeric tau. However we can conclude that macro-
phages display potential in the elimination of oligomeric
tau from the AD brain.Additional file
Additional file 1: Table S1. Raw data used for statistical analysis.
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